GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Akili Inc (NAS:AKLI) » Definitions » COGS-to-Revenue

Akili (AKLI) COGS-to-Revenue : 0.45 (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Akili COGS-to-Revenue?

Akili's Cost of Goods Sold for the three months ended in Mar. 2024 was $0.17 Mil. Its Revenue for the three months ended in Mar. 2024 was $0.38 Mil.

Akili's COGS to Revenue for the three months ended in Mar. 2024 was 0.45.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Akili's Gross Margin % for the three months ended in Mar. 2024 was 54.83%.

Akili COGS-to-Revenue Historical Data

The historical data trend for Akili's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akili COGS-to-Revenue Chart

Akili Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
0.07 0.11 0.66 1.37 0.49

Akili Quarterly Data
Dec19 Sep20 Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.21 1.32 0.40 0.34 0.45

Akili COGS-to-Revenue Calculation

Akili's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0.819 / 1.678
=0.49

Akili's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0.173 / 0.383
=0.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akili  (NAS:AKLI) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Akili's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0.173 / 0.383
=54.83 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Akili COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Akili's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Akili (AKLI) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Akili Inc (NAS:AKLI) » Definitions » COGS-to-Revenue
Comparable Companies
ZCMD STRM EUDA CRVW BEAT OWLT LIFW PBSV ETAO HCTI GEHC VEEV TSE:2413 HQY ASX:PME RCM TXG DOCS PGNY TDOC
Traded in Other Exchanges
AKLI:Mexico
Address
125 Broad Street, Fifth Floor, Boston, MA, USA, 02110
Website
https://www.akiliinteractive.com
Akili Inc is a digital medicine company pioneering the development of cognitive treatments through game-changing technologies.
Executives
Jacqueline Studer officer: Chief Legal Officer IDEXX LABORATORIES, ONE IDEXX DRIVE, WESTBROOK ME 04092
Matthew Franklin officer: See Remarks AKILI INTERACTIVE LABS, INC., 125 BROAD STREET, 5TH FLOOR, BOSTON MA 02110
Martucci Walter Edward Ii director, officer: Chief Executive Officer AKILI INTERACTIVE LABS, INC., 125 BROAD STREET 5TH FLOOR, BOSTON MA 02110
Santosh Shanbhag officer: Chief Financial Officer AKILI INTERACTIVE LABS, INC., 125 BROAD STREET 5TH FLOOR, BOSTON MA 02110
Chamath Palihapitiya director, 10 percent owner THE SOCIAL-CAPITAL PARTNERSHIP, L.L.C., 506 SANTA CRUZ AVENUE, SUITE 300, MENLO PARK CA 94025
Mary Hentges director C/O SHOTSPOTTER, INC., 7979 GATEWAY BLVD., STE. 210, NEWARK CA 94560
Tls Beta Pte. Ltd. 10 percent owner 60B ORCHARD ROAD #06-18, THE ATRIUM@ORCHARD, SINGAPORE U0 238891
Temasek Holdings (private) Ltd 10 percent owner 60B ORCHARD ROAD #06-18 TOWER 2, THE ATRIUM@ORCHARD, SINGAPORE U0 238891
Fullerton Management Pte Ltd 10 percent owner 60B ORCHARD ROAD #06-18 TOWER 2, THE ATRIUM@ORCHARD, SINGAPORE U0 238891
Anil Jina officer: Chief Medical Officer AKILI INTERACTIVE LABS, INC., 125 BROAD STREET 5TH FLOOR, BOSTON MA 02110
Temasek Life Sciences Private Ltd 10 percent owner 60B ORCHARD ROAD #06-18, THE ATRIUM@ORCHARD, SINGAPORE U0 238891
Jonathan David officer: Chief Product Officer AKILI INTERACTIVE LABS, INC., 125 BROAD STREET 5TH FLOOR, BOSTON MA 02110
Kenneth Ehlert director AKILI INTERACTIVE LABS, INC., 125 BROAD STREET, 5TH FLOOR, BOSTON MA 02110
Christine Lemke director AKILI INTERACTIVE LABS, INC., 125 BROAD STREET, 5TH FLOOR, BOSTON MA 02110
Adam Gazzaley director AKILI INTERACTIVE LABS, INC., 125 BROAD STREET, 5TH FLOOR, BOSTON MA 02110